




COPY OF PAPERS  
ORIGINALLY FILED

# 18  
9nd

PATENT  
Docket No. 532732000220

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on July 15, 2002

  
Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Yajun GUO

Serial No.: 09/216,604

Filing Date: December 17, 1998

For: CELLULAR VACCINES AND  
IMMUNOTHERAPEUTICS AND  
METHODS FOR THEIR  
PREPARATION

Examiner: Gerald R. EWOLDT

Group Art Unit: 1644

RECEIVED  
JUL 26 2002  
TECH CENTER 1600/2300

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is in response to the Restriction Requirement mailed March 15, 2002, time for response to which was set to expire April 15, 2002. Applicant respectfully requests an extension of time of 3 (three) months. This extension will set the Response to expire July 15, 2002.

Accordingly, required fee is enclosed.

Restriction under 35 U.S.C. § 121 was required among the following eight (8) groups:

- I. Claim 85, drawn to a method of preparing an immunogenic composition, classified in Class 424, subclasses 277.1 and 278.1, and Class 435, subclass 325;
- II. Claim 86, drawn to a method of preparing an immunogenic composition, classified in Class 424, subclasses 277.1 and 278.1, and Class 435, subclass 325;
- III. Claim 87, drawn to an immunogenic composition comprising an antigen pulsed-dendritic cell, classified in Class 424, subclasses 93.2, 93.71 and 277.1, and Class 435, subclass 325;
- IV. Claim 87, drawn to an immunogenic composition comprising a nucleic acid-transfected dendritic cell, classified in Class 424, subclasses 93.2, 93.71 and 277.1, and Class 435, subclass 362;
- V. Claims 88-89, drawn to a method of preparing a pharmaceutical composition (antigens), classified in Class 424, subclasses 93.2, 93.71 and 277.1, and Class 435, subclass 325;
- VI. Claims 88-89, drawn to a method of preparing a pharmaceutical composition (nucleic acid), classified in Class 424, subclasses 93.2, 93.71 and 277.1, and Class 435, subclasses 325 and 455;
- VII. Claim 90, drawn to a method of preparing a pharmaceutical composition (antigens), classified in Class 424, subclasses 93.2, 93.71 and 277.1, and Class 435, subclass 325; and
- VIII. Claim 90, drawn to a method of preparing a pharmaceutical composition (nucleic acid), classified in Class 424, subclasses 93.2, 93.71 and 277.1, and Class 435, subclasses 325 and 455.

Applicant hereby elects to prosecute the claim of group 1, claim 85. This election is made with traverse. Reconsideration is respectfully requested.

Applicant submits that there is no additional search burden in searching claims 85 and 86 together as these two claims have identical classes and subclasses. Accordingly, applicant requests that the election of group I be extended to group II as well. Similarly, Applicant requests that Groups III, V and VII be recombined into one group because these groups have identical classes and subclasses. Applicants further requests that Groups IV, VI and VIII be recombined into one group because these groups have identical classes and subclasses.

The Examiner has also required Applicant under 35 U.S.C. § 121 to elect a specific target diseased cell and a specific bridge molecule. Applicant hereby elects the methods and compositions wherein the specific target diseased cell is a tumor cell or a hepatocellular carcinoma cell or a Hepa 1-6 cell and the specific bridge molecule is the CD 28:gp 55 bispecific antibody.


#### REMARKS

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the

filing of this document to Deposit Account No. 03-1952 referencing 532732000220. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 15, 2002

Respectfully submitted,

By:   
Peng Chen  
Registration No. 43,543

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5117  
Facsimile: (858) 720-5125